A pharmaceutical company protecting research IP and clinical infrastructure.
An international pharmaceutical company faces nation-state targeting of research IP, regulator scrutiny of clinical infrastructure, and brand-impersonation campaigns timed to clinical-trial milestones. Continuous external monitoring covers the surface; CTI Threat Actor Intelligence tracks the actor groups targeting pharma specifically.
International pharmaceutical company with multi-region operations.
An international pharmaceutical company with multi-billion-USD annual revenue, operating R&D, manufacturing, and commercial operations across multiple regulatory regions. Research portfolio spans multiple therapeutic areas; clinical-trial infrastructure operates across dozens of countries.
External surface includes corporate infrastructure, R&D-program portals, clinical-trial systems, partner integrations with CROs (contract research organizations), and patient-facing infrastructure for trial recruitment. Adversaries operate under varied threat profiles: nation-state actors targeting research IP, financially-motivated groups targeting payment systems, hacktivist groups targeting public-health-controversy moments.
Sector-specific actor framing across research, clinical, and commercial.
Nation-state targeting + clinical-trial systems across dozens of jurisdictions + brand-impersonation around trial-result announcements + executive threat exposure for scientific leadership. Generic exposure tooling didn't have sector-specific framing.
The challenge.
Research IP infrastructure attractive to nation-state actors. Clinical-trial systems span dozens of jurisdictions with overlapping regulatory exposure. Brand-impersonation campaigns spike around trial-result announcements. Executive threat exposure elevated for scientific leadership during high-visibility moments. Generic exposure tooling didn't have sector-specific actor framing.
The workflow change.
Deepinfo deployed across research, clinical, manufacturing, and commercial infrastructure. CTI Threat Actor Intelligence configured for nation-state groups historically active against pharma + financially-motivated targeting payment systems. CTI Executive Threat Monitoring extended to scientific leadership. BRP catches fraudulent-domain impersonation around trial milestones. TPRM extends to CRO and clinical-services vendor base.
The outcome.
Research and clinical infrastructure under unified monitoring. Sector-specific actor intelligence drives prioritization. Executive threat protection runs continuously rather than reactively. Vendor scoring across the pharma tech stack.
Concrete outcomes across the pharma operation.
- Research and clinical infrastructure under unified monitoring: single platform across the full external footprint.
- Sector-specific actor intelligence: TTPs mapped to MITRE ATT&CK for groups historically active against pharma.
- Executive threat protection: protective intelligence for scientific leadership during high-visibility periods.
- Vendor scoring across the pharma tech stack: CROs, clinical-services vendors, manufacturing partners.
- Brand-impersonation defense around regulatory milestones: trial-result announcements, FDA-decision windows.
More customer stories.
An international humanitarian foundation protecting donor trust and field operations.
An international humanitarian and healthcare foundation operating field programs across dozens of countries faces external threats that mix brand impersonation (fake donation…
Read story CUSTOMER STORYA healthcare system protecting patient data and continuity of care.
An integrated health system operating across 12 hospitals, dozens of physician practices, and multiple specialty clinics combined HIPAA-compliance evidence pressure with the…
Read story CUSTOMER STORYA manufacturing group monitoring exposure across facilities and supply chain.
An international manufacturing group operates facilities across 20+ regions with tier-1 and tier-2 supplier networks spanning continents.
Read storySee exposure across your research, clinical, and commercial surface.
Run Deepinfo against your domain. The platform scales to pharma surface sizes; threat-intelligence framing matches the sector adversary reality.